Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2026-03-03 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
关于向特定对象发行股票发行结果暨股本变动公告
Share Issue/Capital Change Classification · 100% confidence The document is a detailed announcement regarding the results of a specific share issuance to designated investors by Shenzhen Microchip Biotechnology Co., Ltd. It includes information on the number of shares issued, pricing, total funds raised, regulatory approvals, internal decision-making processes, shareholder meeting approvals, and changes in shareholding structure. The document also details the registration and listing of the new shares, the lock-up period, and the identities and backgrounds of the investors involved. This is a comprehensive disclosure about a capital raising event and the resulting changes in the company's capital structure. It is not a general financial report, earnings release, or management discussion, but specifically an announcement about a share issuance and capital change. Therefore, the appropriate classification is "Share Issue/Capital Change (SHA)". The document length and detail confirm it is the announcement itself, not a brief notice or a report publication announcement.
2026-03-03 Chinese
关于使用部分暂时闲置募集资金进行现金管理及募集资金余额以协定存款方式存放的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the use of temporarily idle raised funds for cash management and the deposit of raised funds balance in agreed deposits. It details the board resolution, investment purpose, amount, duration, types of investment products, risk control measures, and the legal compliance and approval process. The document is a formal disclosure about the company's capital management activities related to raised funds, not a financial report or audit. It is not an annual or interim report, earnings release, or management discussion. It is a regulatory announcement about capital usage and cash management, fitting the category of Capital/Financing Update (CAP). The document length is 3905 characters, which is typical for an announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2026-03-03 Chinese
关于使用部分募集资金向全资子公司实缴出资、增资及提供借款以实施募投项目的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shenzhen Microcore Biotech Co., Ltd. regarding the use of part of the raised funds to make paid-in capital contributions, capital increases, and provide loans to its wholly-owned subsidiary to implement a fundraising investment project. It details the amounts, the projects, the board approval, and regulatory compliance. The document is relatively short (3400 characters) and focuses on the announcement of the use of fundraising proceeds rather than presenting financial statements or audit results. It does not contain comprehensive financial data or detailed financial performance analysis. It is not an annual or interim report, nor an audit report. The content fits the category of a Capital/Financing Update (CAP) as it relates to the use of raised capital and financing activities within the company and its subsidiary.
2026-03-03 Chinese
国投证券股份有限公司关于深圳微芯生物科技股份有限公司2024年度向特定对象发行A股股票之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" which translates to "Listing Sponsorship Letter" or "Sponsorship Document" related to a specific issuance of A shares by Shenzhen Chipscreen Biosciences Co., Ltd. It is issued by the sponsor (Guotou Securities Co., Ltd.) and contains detailed information about the issuer, the issuance, business overview, financial data, risk factors, and regulatory compliance. The document references laws and regulations related to securities issuance and listing on the Shanghai Stock Exchange's STAR Market. It is a comprehensive document supporting a capital raising event through a specific share issuance to targeted investors. This type of document is typically classified as a Capital/Financing Update (CAP) because it relates to the company's fundraising activity and issuance of new shares to specific investors. It is not an annual report, earnings release, or other report type, but a detailed sponsorship document for a share issuance. The document length (15,000 characters) and content confirm it is the actual sponsorship document, not just an announcement of a report publication. Therefore, the correct classification is CAP with high confidence.
2026-03-03 Chinese
深圳微芯生物科技股份有限公司2024年度向特定对象发行A股股票上市公告书
Capital/Financing Update Classification · 95% confidence The document is titled as a "2024年度向特定对象发行A股股票上市公告书" which translates to "2024 Annual Announcement of Specific Object Issuance of A Shares Listing" by Shenzhen Chipscreen Biosciences Co., Ltd. It details the issuance of new shares, including the number of shares, pricing, subscription process, regulatory approvals, and listing arrangements. The document includes extensive information about the issuance process, pricing, allotment, regulatory approvals, and shareholder meetings related to the issuance. This is a detailed announcement about a capital raising event through a specific share issuance to targeted investors, including the listing of these new shares on the Shanghai Stock Exchange. It is not a general annual report, earnings release, or management discussion. It is not a proxy statement or voting results announcement. It is clearly an announcement related to capital raising and financing activities. Therefore, the document fits best under the category "Capital/Financing Update (CAP)" which covers updates on company fundraising, financing activities, or capital structure changes. The document length and detail confirm it is not a mere announcement of a report but a substantive disclosure about the financing event.
2026-03-03 Chinese
国投证券股份有限公司关于深圳微芯生物科技股份有限公司使用部分暂时闲置募集资金进行现金管理及募集资金余额以协定存款方式存放的核查意见
Regulatory Filings Classification · 85% confidence The document is a sponsor’s formal "核查意见" (verification opinion) by 国投证券 regarding Shenzhen Microcore Bio-tech’s use of idle IPO‐raised funds for cash management and deposits. It is a compliance and regulatory verification letter, not a full financial report (10-K, IR), not a simple announcement of report publication, not a management change notice, nor a dividend or share issue proxy. It does not present substantive financial statements or investor presentation materials. It fits the definition of a general regulatory announcement/compliance document, thus falls under Regulatory Filings (RNS).
2026-03-03 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.